Lornoxicam  (Synonyms: Chlortenoxicam; Ro 13-9297)

Lornoxicam (Chlortenoxicam) is an orally active oxycontin nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antipyretic and anticancer activities. Lornoxicam exhibits good inhibitory effects on both COX-1 and COX-2 (COX-1: IC₅₀=0.005 μM; COX-2:IC₅₀=0.008 μM) and inhibits the production of NO by iNOS (IC₅₀=65 μM) and the proinflammatory cytokine IL-6 (IC₅₀=54 μM). Lornoxicam also inhibits tumor cell proliferation and migration and induces tumor cell apoptosis. Lornoxicam can be used in the study of inflammatory pain, colorectal cancer and breast cancer^{[1][2][3][4][5][6][7]}.

Lornoxicam (0.03-3 μM; 24 h) dose-dependently inhibites the formation of TXB2 in HEL cells, the formation of PGF1 in Mono Mac 6 cells stimulated by LPS (HY-D1056) and the accumulation of NO in the supernatant of RAW 264.7 cells stimulated by LPS (HY-D1056)^[6].
Lornoxicam (10-300 μM; 10 min) dose-dependently inhibites the formation of IL-6 in human monocytic THP-1 cells (IC₅₀=54 μM) and weakly stimulates the production of TNF-a, IL-1b and IL-8 at a dose of 300 μM^[6].
Lornoxicam (3.1-400 μg/mL; 0-48 h) concentration-dependently induces a decrease in the viability of cervical cancer, colorectal cancer, and breast cancer cell lines HeLa, MCF-7, and HT-29 and inhibites the proliferation of HT-29 cell line^[7].
Lornoxicam (400 μg/mL; 24 h) induces apoptosis in HT-29 and MCF-7 tumor cells^[7].
Lornoxicam (400 μg/mL; 0-72 h) inhibites the migration of HT-29 and MCF-7 tumor cells^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lornoxicam (1.3 mg/kg, i.p.; single dose) reduces the ability of central sensitization in rats to reduce hyperalgesia in the thermal hind paw hyperalgesia model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

371.82

C₁₃H₁₀ClN₃O₄S₂

70374-39-9

Solid

Light yellow to yellow

O=C(C1=C(O)C2=C(C=C(Cl)S2)S(N1C)(=O)=O)NC3=NC=CC=C3

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

• [1]. Spyra S, et al. COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels. Br J Pharmacol. 2017 Aug;174(16):2696-2705.  [Content Brief]

  [2]. Rose, P. and C. Steinhauser, Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig, 2004. 24(4): p. 227-36.  [Content Brief]

  [3]. Bianchi, M. and A.E. Panerai, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res, 2002. 45(2): p. 101-5.  [Content Brief]

  [4]. Balfour J A, et al. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J]. Drugs, 1996, 51: 639-657.  [Content Brief]

  [5]. Pohlmeyer-Esch G, et al. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats[J]. Food and chemical toxicology, 1997, 35(9): 909-922.  [Content Brief]

  [6]. Berg J, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro[J]. Inflammation Research, 1999, 48: 369-379.  [Content Brief]

  [7]. Marinov L, et al. The effects of meloxicam, lornoxicam, ketoprofen, and dexketoprofen on human cervical, colorectal, and mammary carcinoma cell lines[J]. Pharmacia, 2024, 71: 1-12.